Buy exelon

Exelon

Such gradual replacement of the abused drug controls the effects of withdrawal, thereby reducing the patient’ s discomfort and associated risks. Exelon has filed its proxy solicitation materials and requests that its proposal to solicit proxies be permitted to become effective immediately, as provided in rule 62 d ; under the Act. It appears to the Commission that the Declaration, with respect to the proposed solicitation of proxies, should be permitted to become effective immediately under rule 62 d.
The patch is an important new addition t o existing oral treatment options since it provides visual reassurance that patients have `taken' their medicine, " said Bruno Dubois, Professor of Neurology at the Hpital Piti Salptrire, Centre de Neuropsychologie, Paris, France. "Just having to apply a patch can help reduce the burden of daily life for people with Alzheimer's disease and their families." Designed with compliance in mind, the patch was preferred by more than 70% of caregivers as a method of drug delivery because it helped them follow treatment schedules and was easier to use than an oral medicine2. "People with Alzheimer's disease and their caregivers welcome every new therapy for the disease, " said Mark Wortmann, Executive Director of Alzheimer's Disease International an umbrella organization of Alzheimer Associations around the world which offer support and advice to people with the disease and their carers. "I pleased that the patch offers a new approach to treatment." Exslon rivastigmine ; in capsule form has been approved since 1997 to treat patients with mild to moderate Alzheimer's disease in more than 70 countries. Since 2006, Exelkn in capsule form or oral solution has been the only member of the cholinesterase inhibitor class of medicines that is approved in both Europe and the US for treating mild to moderate Alzheimer's disease as well as Parkinson's disease dementia. On July 6, 2007, the US Food and Drug Administration FDA ; approved Eexlon Patch rivastigmine transdermal system ; for the treatment of mild to moderate Alzheimer's disease and Parkinson's disease dementia. Alzheimer's disease affects one in 10 people over age 65, making it the most common form of dementia3. The global direct costs of dementia in 2003, for example, were estimated at USD 156 billion 4. Disclaimer The foregoing release contains forward-looking statements that can be identified by terminology such as "potential", "can", "estimated", or similar expressions, or by express or implied discussions regarding potential future revenues from Exslon Patch. Such forwardlooking statements reflect the current views of the Company regarding future events, and involve known and unknown risks, uncertainties and other factors that may cause actual results with 3xelon Patch to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no guarantee that Exelon Patch will achieve any particular levels of revenue in the future. In particular, management's expectations regarding Exelon Patch could be affected by, among other things, unexpected clinical trial results, including unexpected new clinical data and unexpected additional analysis of existing clinical data; competition in general; government, industry and general public pricing pressures; the company's ability to obtain or maintain patent or other proprietary intellectual p roperty protection; unexpected regulatory actions or delays or government regulation generally, and other risks and factors referred to in Novartis AG's current Form 20 -F on file with the US Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated, believed, estimated or expected. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward -looking statements contained in this press release as a result of new information, future events or otherwise. Now many insurances and workers compensations cover it, md's are learning it, it's always in the news, sports teams are using it.

Discount generic Exelon

Are currently estimated to be lower than those of competing fossil fuel technologies.2 Although eight U.S. nuclear reactors have permanently shut down since 1990, recent reactor sales could indicate greater industry interest in nuclear plants that previously had been considered marginal. Despite the shutdowns, annual U.S. nuclear electrical output increased by about one-third from 1990 to 2003, according to the Energy Information Administration. The increase resulted primarily from reduced downtime at the remaining plants, the startup of five new units, and reactor modifications to boost capacity. A spike in fossil fuel prices and shortages of electricity during 2000-2001 helped encourage at least three nuclear operating companies to consider building new commercial nuclear reactors. Entergy, Dominion Resources, and Exelon have chosen sites in Mississippi, Virginia, and Illinois, respectively, for possible future nuclear units and filed early site permit applications with NRC see [ : nrc.gov reactors new-licensing license-reviews esp ] ; in fall 2003. The Department of Energy DOE ; is assisting the site-selection efforts as part of a program to encourage construction of new commercial reactors by 2010. A conference agreement reached November 17, 2003, on omnibus energy legislation H.R. 6 ; would provide tax credits for electricity produced from as much as 6, 000 megawatts of new nuclear generating capacity and authorize about .1 billion for a demonstration reactor in Idaho to produce hydrogen. The Secretary of Energy would be required to study the feasibility of locating a commercial nuclear power plant at a DOE site. The House approved the conference report November 18, 2003, but a Senate filibuster has left the bill's future uncertain. The nuclear energy tax credits were excluded from a modified energy bill introduced February 12, 2004 S. 2095 ; , and the tax provisions of S. 2095 were included in a larger tax bill S. 1637 ; passed by the Senate May 11, 2004. Global warming that may be caused by fossil fuels -- the "greenhouse effect" -- is cited by nuclear power supporters as an important reason to develop a new generation of reactors. An air pollution bill introduced April 9, 2003, by Senator Carper S. 843 ; would provide potentially valuable emissions allowances to owners of incremental nuclear power capacity. On May 19, 2003, New Hampshire became the first state to provide emissions credits for incremental nuclear generating capacity. But the large obstacles noted above must still be overcome before electric generating companies will risk ordering new nuclear units. For more on the outlook for nuclear power, see CRS Report RL31064, Nuclear Power: Prospects for New Commercial Reactors. For the first time, students from The Joffrey Ballet's Strobel Step-Up Program took the stage as an ensemble, performing Angelitos Negros, choreographed by current Joffrey dancer Derrick Agnoletti. The performance was part of Dance Slam, a concert series within Dance Chicago. Mr. Agnoletti created this riveting work for the final showcase of The Joffrey's Gallery 37 Summer Intensive, held at Chicago Park District's Tuley Park. Sixteen apprentices from the summer program mesmerized audiences with Angelitos Negros, performed to the song of the same title. The select groups invited to perform in Dance Slam were judged by a panel of professionals on production quality, technique, performance quality and choreography. The judges ranked Strobel Step-Up students as the highest scoring group for performance quality. The Strobel Step-Up Program is generously sponsored by Exelon Corporation, with additional support provided by the Gaylord and Dorothy Donnelley Foundation and Pamela and Russ Strobel. To learn more about Joffrey Education Community & Engagement programs and how you can get involved, e-mail education joffrey or call Pierre Lockett at 312.386.8931 and kytril. For Exelon, also includes corporate operations, shared service entities, including Exelon Business Services Company BSC ; , Enterprises and investments in synthetic fuel-producing facilities. For Generation, includes buildings under capital lease with a net carrying value of million at December 31, 2006. The original cost basis of the buildings was million and total accumulated amortization was million at December 31, 2006. For ComEd and PECO, represents non-utility property. b ; For Generation, includes accumulated amortization of nuclear fuel of , 078 million at December 31, 2006. December 31, 2005 Exelon. Rabies rabies is a virus which affects the nervous system and leukeran. The inspector reviewed the corrective action effectiveness review for corrective actions completed for the RCA. Prior to this inspection, Exelon performed an assessment of the corrective actions associated with the cardox discharge event. The corrective actions were graded on completeness and thoroughness of supporting documentation. Items receiving low grades resulted in additional condition reports for further action. Furthermore, the EP department, with the support of the operations training department, had just completed a series of simulator drills with non-standard EAL entry conditions. Personnel responsible for making classifications made the appropriate classifications during these drills.

Exelon drug interactions

Progress in harmonization 45. Considerable progress has been made recent years in harmonizing development assistance in Uganda. Progress includes: Meeting every month as the local development partners group to discuss economic and governance issues; and excluding the World Bank and AfDB ; meeting as the Partner for Democracy and Governance to discuss the key political governance issues in Uganda.14 Increasingly coordinating provision of budget support as the main instrument for supporting implementation of the PEAP, harmonized around PRSCs and the government's budget process. Closely coordinating budget support operations, including the PRSCs, with the Poverty Reduction and Growth Facility PRGF ; of the IMF. Increasingly coordinating and sharing analytical and advisory work, appraisals and reviews, fiduciary assessments, and accountability rules for example, the multidonor country integrated fiduciary assessment and analytical work on gender and poverty ; . Increasingly coordinating sector support by supporting a number of mature SWAps, engaging with government sector working groups, using basket funding mechanisms, and bringing development partner-funded projects into alignment with sector strategies. Partners are providing assistance through SWAps for health, education, water, HIV AIDS, and justice, law, and order that bring together all development partners in these sectors. In addition, partners have adopted joint financing arrangements for strengthening of local government, and for technical assistance for public financial management. A number of development partners are pooling their funds in support of regional programs, such as the Multicountry Demobilization and Reintegration Program. Increasingly pursuing joint policy dialogue. All partners participate in a joint dialogue on the public expenditure review, and in the joint dialogue on the north through a Donor Technical Group. All bilateral partners are coordinating dialogue on governance and human rights through the Partners for Democracy and Governance Group. Adopting silent partnerships in which one development partner formally represents another in policy and sector dialogue, a practice that has significantly reduced transactions costs of dialogue for both development partners and the government. Increasingly adopting joint development partner approaches to supporting nonstate sectors. Joint working groups on civil society and on private sector development have been established. Future directions in harmonization 46. The UJAS partners will build on progress made in harmonization. They will seek to increase their selectivity in the use of aid modalities, and development partners who are able to provide general and sector budget support will make this their priority. 47. All development partners are increasingly aware that there is still substantial scope for harmonizing approaches to the provision of budget support. Aligning budget support timetables and the framework for decisions is an important objective for the early stages of the implementation of the UJAS and viramune. Less than 40% actually worry about a fatal plane crash, and these people are most likely to benefit from fear of flying courses. There is some debate as to the usefulness of urinalysis as an adjunct in the clinical decision making process related to urinary tract infection. However, it is generally supported that abnormal findings at urinalysis are a relatively reliable indicator that some type of disease process may be present. Abnormal findings should be viewed in conjunction with presenting signs and symptoms, history and assessment findings and other patient related factors. see appendix P and mysoline.

Cost of Exelon

It should not be used by persons who have auto-immune disease such as lupus erythromatosus, multiple sclerosis HIV AIDS, or collagen disease or by those with tuberculosis or hypersensitivity to herbs of family Asteraceae. Immuno-superssion may occur after extended therapy with this herb, do not use for longer than 8 weeks without a 3 weeks rest period. Echinaceae should not be used during pregnancy one study showed no harmful effects during the first trimester ; and lactation and should not be given for children younger than two years of age. The prices indicate when and where the transmission system needs to be expanded or generation needs to be built. MYTH: Some contend that restructured companies aren't capable of running reliable systems and repairing storm damage; only "integrated" companies can. False. The statement is [both absurd and] offensive because it ignores the fact that crews from utilities like ComEd and PECO in restructured companies frequently help repair storm damage at utilities in integrated systems. The delivery side of the electricity business is a separate and distinct business function from generating electricity even in an integrated company. Both ComEd and PECO run reliable systems, and industry metrics show that they consistently rank in the first and second quartile for reliability. "Real" customers don't support competitive markets False. Many "real" customers, including many of the country's largest electricity consumers, believe they have benefited greatly from organized markets. For example, on December 4, 2006, some of the largest "real" customers in the Nation sent a letter to Chairman Kelliher endorsing competitive markets. The customers include 7-Eleven, Inc., A&P, the Archdiocese of Chicago, Best Buy Co., Inc., Big Lots Stores, Inc., the Chemistry Council of New Jersey, Federated Department Stores, and Wal-Mart Stores, Inc., and represent nearly 14, 000 facilities with over .5 billion in annual electricity costs. No one is building transmission. False. Between 2000 and 2006 Exelon ComEd and PECO ; has invested nearly billion in transmission. ComEd's West Loop transmission project, which is currently under construction, is the most expensive and most complex transmission investment ever made by ComEd at a cost of 5 million. The Edison Electric Institute recently conducted a comprehensive survey entitled "Transmission Projects: At A Glance" January 2007 ; that documents ongoing projects and recent investments and oxytrol.

Ask answer discover my profile home health diseases & conditions other - diseases resolved question shonda member since: 24 july 2006 total points: 1365 level 3 ; add to my contacts block user resolved question show me another » thyroid levels: t4 high tsh normal.

Exelon pa peach bottom 2 nuke dips to 67 percent power and topamax. Exelon's costs of providing pension and postretirement benefit plans are dependent upon a number of factors, such as the rates of return on pension plan assets, discount rate, and the rate of increase in health care costs. The market value of plan assets was affected by sharp declines in the equity market from 2000 through 2002. As a result, at December 31, 2002, Exelon was required to recognize an additional minimum liability and an intangible asset as prescribed by SFAS No. 87. The liability was recorded as a reduction to shareholders' equity, and the equity will be restored to the balance sheet in future periods when the fair value of plan assets exceeds the ABO. The amount of the reduction to shareholders' equity net of income taxes ; in 2002 was .0 billion. The recording of this reduction did not affect net income or cash flows in 2002 or compliance with debt covenants. In.
1. Small G, Rabins P, Barry P, et al. Diagnosis and treatment of Alzheimer disease and related disorders: consensus statement of the American Association for Geriatric Psychiatry, the Alzheimer's Association, and the American Geriatrics Society. JAMA 1997; 278: 13631371 Knopman D, Donohue J, Gutterman E. Patterns of care in the early stages of Alzheimer's disease: impediments to timely diagnosis. J Geriatr Soc 2000; 48: 300304 McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984; 34: 939944 Lim A, Tsuang D, Kukull W, et al. Clinico-neuropathological correlation of Alzheimer's disease in a community-based case series. J Geriatr Soc 1999; 47: 564569 Rasmusson D, Brandt J, Steele C, et al. Accuracy of clinical diagnosis of Alzheimer disease and clinical features of patients with non-Alzheimer disease neuropathology. Alzheimer Dis Assoc Disord 1996; 10: 180188 Gearing M, Mirra SS, Hedreen JC, et al. The Consortium to Establish a Registry for Alzheimer's Disease CERAD ; , pt 10: neuropathology confirmation of the clinical diagnosis of Alzheimer's disease. Neurology 1995; 45 3 pt 1 ; 461466 7. Lopez O, Becker J, Klunk W, et al. Research evaluation and diagnosis of probable Alzheimer's disease over the last two decades, 1. Neurology 2000; 55: 18541862 Folstein MF, Folstein SE, McHugh PR. Mini-Mental State: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12: 189198 Sunderland T, Hill J, Mellow A, et al. Clock drawing in Alzheimer's disease: a novel measure of dementia severity. J Geriatr Soc 1989; 37: 725729 Pfeffer R, Kurosaki T, Harrah CJ, et al. Measurement of functional activities in older adults in the community. J Gerontol 1982; 37: 323329 Hachinski V, Lassen N, Marshall J. Multi-infarct dementia: a cause of mental deterioration in the elderly. Lancet 1974; 2: 207210 Doody RS, Stevens JC, Beck C, et al. Practice parameter: management of dementia an evidence-based review ; . Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2001; 56: 11541166 Sano M, Ernesto C, Thomas RG, et al. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease: the Alzheimer's Disease Cooperative Study. N Engl J Med 1997; 336: 12161222 Francis P, Palmer A, Snape M, et al. The cholinergic hypothesis of Alzheimer's disease: a review of progress. J Neurol Neurosurg Psychiatry 1999; 66: 137147 Aricept [package insert]. Teaneck, NJ: Eisai Inc; 2001 16. Reminyl [package insert]. Titusville, NJ: Janssen; 2001 17. Exelon [package insert]. East Hanover, NJ: Novartis; 2001 18. Winblad B, Engedal K, Soininen H, et al. A 1-year, randomized, placebocontrolled study of donepezil in patients with mild to moderate AD. Neurology 2001; 57: 489495 Mohs R, Doody R, Morris J, et al. A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients. Neurology 2001; 57: 481488 Doody R, Geldmacher D, Gordon B, et al. Open-label, multicenter, phase III extension study of the safety and efficacy of donepezil in patients with Alzheimer's disease. Arch Neurol 2001; 58: 427433 Rogers S, Doody R, Pratt R, et al. Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: final analysis of a US multicentre open-label study. Eur Neuropsychopharmacol 2000; 10: 195203 Raskind M, Peskind E, Wessel T, et al. Galantamine in AD: a 6-month randomized, placebo-controlled trial with a 6-month extension. Neurology 2000; 54: 22612268 Farlow M, Anand R, Messina JJ, et al. A 52-week study of the efficacy of rivastigmine in patients with mild to moderately severe Alzheimer's disease. Eur Neurol 2000; 44: 236241 Feldman H, Gauthier S, Hecker J, et al. A 24-week, randomized, doubleblind study of donepezil in moderate to severe Alzheimer's disease. Neurology 2001; 57: 613620 Rosler M, Anand R, Cicin-Sain A, et al. Efficacy and safety of rivastig and atrovent.

Mark martin will make one final effort to win the nascar championship that's eluded him the past 26 years by driving for storied hendrick motorsports next season.
Save about 00 annually, and a 2-point increase in an MMSE score, rather than a 2-point decline, would save about 00.6 Cholinesterase inhibiters are used in AD to attempt to preserve cognition and function, and avoid behavioral complications of the disease. The three cholinesterase inhibiters, donepezil Aricept ; , galantamine Razadyne ; , and rivastigmine Exelon ; , are approved for use in mild to moderate AD and are similar in efficacy. Exhibit 6 outlines some benefits of pharmacologic therapy. An economic study of donepezil examined the and combivent.
Diovan Co-Diovan Gleevec Glivec Lamisil group ; Zometa Neoral Sandimmun Lotrel Sandostatin incl. LAR ; Lescol Voltaren group ; Trileptal Top ten products Visudyne Exelon Tegretol incl. CR XR ; Femara Miacalcic Elidel Foradil Leponex Clozaril Zelnorm Zelmac Famvir Top twenty products Rest of portfolio Total!

Energy Delivery and Exelon Energy Company. Sales to affiliates decreased primarily due to lower volume sales to ComEd, offset by slightly higher prices. Sales to PECO were lower, primarily due to lower prices, offset slightly by higher volumes. Sales to Exelon Energy Company decreased primarily due to the discontinuance of Exelon Energy Company operations in the PJM region. Other. Revenues also increased in 2003 as compared to 2002, as a result of a million increase in sales of excess fossil fuel. The increased excess fossil fuel is a result of generating plants in the Texas and New England regions operating at less than projected levels. Also, revenue increased by million due to higher decommissioning revenue received from ComEd in 2003 compared to 2002. Purchased Power and Fuel Expense. The changes in Generation's purchased power and fuel expense for 2003 compared to 2002 consisted of the following and synthroid and Buy exelon. Boom and bust cycle we have experienced over the past decade has made developers very, very wary of committing to new projects without some form of financial certainty. And banks simply will not lend the millions of dollars necessary to build generation in an uncertain regulatory environment. That is why we need a forward capacity procurement requirement. The best way that PJM can accomplish this objective in a market environment is to use a forward commitment process that allows sufficient time for new generation entrants to submit a competitive offer, be committed through the auction, and subsequently to build in time for the start of the delivery year. Exelon believes that incorporating forward procurement in PJM's RPM will be a significant improvement that will permit new entrants the realistic opportunity to bid sufficiently far ahead to have time to build. Under forward procurement, if a new resource is needed to meet the planning reserve margin, the most competitive offer from a planned unit will clear the auction. The planned unit then has four years as opposed to one day -- to complete construction and be able to deliver when the capacity is needed. Similarly, adding a forward procurement process will allow a retirement candidate with relatively high "going forward costs" to bid to "commit" to continue providing service in the future. Again, if the unit bids cover the cost of continued operation, and that unit clears in the auction, then PJM knows that the units will be available for service in that future year to meet the reliability needs.2 A market design that as a practical matter precludes new entrants or retirement candidates from bidding to serve load in the future is ignoring potential economic resources and thereby may be failing to optimize the mix of resources needed for system reliability. Forward procurement allows PJM to satisfy the planning reserve margin at the least cost and is critical to ensuring reliability and maintaining robust wholesale competition. Under the forward procurement model, PJM commits to suppliers to purchase capacity to serve the aggregate projected load each year for four years in the future. Retail suppliers that choose to self-supply may do so and may commit to PJM for those years the amount they choose to self-supply. Retail suppliers in competitive markets whose loads may vary from year to year pay only for load they actually serve during the year of delivery. Thus retail suppliers are not obligated to buy supply they do not need because of "load switching." PJM allocates capacity payments to such entities based on the load that they actually serve in the delivery year. Large retail customers also will have the option of bidding to self-supply, of offering a demand response, or of relying on PJM's purchases for their future needs.

Exelon oral

Criteria are established to bound and ensure an acceptable level of health and safety as measured by the risks of radiological consequences. Exelon has purportedly selected TLRC that are independent of reactor type and site and use well-defined and quantifiable risk metrics. The TLRC identified by Exelon, which are described as updates of TLRC presented by DOE in support of the MHTGR in 1989, are plotted in Figure 2 and detrol. In product information it mentions that headaches are a possible side effect. Exelon sponsors defined benefit pension plans and postretirement welfare benefit plans applicable to essentially all ComEd, PECO, Generation and Exelon Business Services Company BSC ; employees and certain employees of Enterprises. Essentially all management employees, and electing union employees, hired on or after January 1, 2001 participate in Exelon sponsored cash balance pension plans. They were sold to exelon because there were operations problems. What types of sleep difficulties do people with M.E. have? Sleep disorders seem to be part of the underlying disease process in M.E., probably because the brain's control mechanisms for sleep are affected. Problems can also occur as a result of other symptoms or factors in M.E. For example, you might be kept awake at night by muscle pain. This can create a vicious circle where lack of sleep worsens symptoms and reduces your ability to cope with the illness. Sleep difficulties common to people with M.E. include: insomnia or difficulty getting to sleep light, dreamy, restless sleep excessive REM sleep ; waking too early in the morning unrefreshing sleep hypersomnia excessive sleepiness or sleep lasting for very long periods ; sleep reversal for example, sleeping from 4am till midday. Of insults and, at a molecular level, has been shown to serve as an NMDA receptor antagonist [8]. Thus, novel lead compounds, based on the ; -HupA scaffold, may have a broad spectrum of pharmacological actions, and not serve merely as anticholinesterase anti-ChE ; agents. AD is a neurological disorder characterized by a significant decrease in hippocampal and cortical levels of the neurotransmitter acetylcholine ACh ; , leading to severe memory and learning deficits [11]. According to the "cholinergic hypothesis" [12], inhibition of AChE in the central nervous system can alleviate these deficits; indeed, all first-generation AD drugs are cholinesterase inhibitors ChEIs ; , including the synthetic compounds tacrine Cognex ; [13, 14], donepezil Aricept ; [2-4] and rivastigmine Exelon ; [6], and the alkaloids ; galanthamine Reminyl ; [5] and ; -HupA see above ; . It has long been known that AChE has an enhanced affinity for bifunctional inhibitors such as the bis-quaternary inhibitors, decamethonium DECA ; [15], BW284c51 [16] and ambenonium [17] Fig. 1 ; [18]. It was postulated that this is due to the existence of two binding sites in the enzyme [15]. These sites bind to the bivalent ligands simultaneously, giving rise to what is known as the "chelate effect". This is a well-known thermodynamic phenomenon that is manifested as the enhanced stability of a complex formed from bi- or polyvalent ligands and their targets, compared to a similar complex formed from the monovalent counterparts. This enhanced stability is the result of a decrease in entropic penalty for binding a single large ligand versus two smaller and buy kytril.
Aricept and other medicine top aricept and other medicine resources our top aricept and other medicine resource acetylcholinesterase inhibitors in the treatment of alzheimer's: aricept, reminyl, exelon subsequent research has shown that all people need some breakdown of acetylcholine in their brains while sleeping to reach the deeper, more restful stages of sleep.

Exelon what is

Exelon children

Exekon, exelpn, exelkn, exwlon, xelon, sxelon, ezelon, exeoln, exel0n, ex4lon, 3xelon, edelon, exeloon, wxelon, exepon, exellon, exelin, 4xelon, exelno, exleon, eexlon, exelom, exelob, exflon.